文献速递核素与放射性配体治疗肿瘤 PET/CT

与谷氨酸羧肽酶III的交叉反应导致PSMA靶向小分子放射性核素治疗药物在唾液腺和肾脏的非期望摄取

Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-10-03

该研究通过比较PSMA与全人类蛋白质组的序列,鉴定出与PSMA相似度最高的胞外靶点包括GCPIII、NAALADL-1和TfR1。荧光偏振实验显示Pluvicto™荧光衍生物(化合物1)与PSMA及GCPIII紧密结合,与NAALADL-1和TfR1无相互作用。免疫荧光分析显示GCPIII在健康人肾脏和唾液腺中大量表达,作者认为这可能是Pluvicto™及其他Glu-ureido类PSMA放射性药物在患者体内非期望蓄积的原因。

要点

  • Pluvicto™荧光衍生物(化合物1)在荧光偏振实验中与PSMA及GCPIII紧密结合,与NAALADL-1和TfR1无相互作用。
  • 免疫荧光分析显示GCPIII在健康人肾脏和唾液腺中大量表达。
  • 作者认为肾脏和唾液腺中GCPIII的膜表达可能是Pluvicto™及其他Glu-ureido类PSMA放射性药物非期望蓄积的原因。

核心结论

  • 作者认为肾脏和唾液腺中GCPIII的膜表达可能是Pluvicto™及其他Glu-ureido类PSMA放射性药物在患者体内非期望蓄积的原因。

研究设计与样本

  • 研究比较PSMA序列与全人类蛋白质组以鉴定与靶点密切相关的蛋白质。
  • 通过荧光偏振测定化合物1对PSMA、GCPIII、NAALADL-1和TfR1的亲和力。
  • 使用市售抗体通过免疫荧光评估推定抗靶点GCPIII在人唾液腺和肾脏中的表达。

主要发现

  • 鉴定出谷氨酸羧肽酶III(GCPIII)、N-乙酰化α连接酸性二肽酶样1(NAALADL-1)和转铁蛋白受体1(TfR1)为与PSMA相似度最高的胞外靶点。
  • Pluvicto™的荧光衍生物(化合物1)在荧光偏振实验中与PSMA和GCPIII紧密结合,而与NAALADL-1和TfR1未观察到相互作用。
  • 免疫荧光分析显示GCPIII在健康人肾脏和唾液腺中均大量表达。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recently, Pluvicto™ ([177Lu]Lu-PSMA-617), a small-molecule prostate-specific membrane antigen (PSMA) radioligand therapeutic, has been approved by the FDA in metastatic castration-resistant prostate cancer. Pluvicto™ and other PSMA-targeting radioligand therapeutics (RLTs) have shown side effects due to accumulation in certain healthy tissues, such as salivary glands and kidney. Until now, the molecular mechanism underlying the undesired accumulation of PSMA-targeting RLTs had not been elucidated. METHODS: We compared the sequence of PSMA with the entire human proteome to identify proteins closely related to the target. We have identified glutamate carboxypeptidase III (GCPIII), N-acetylated alpha-linked acidic dipeptidase like 1 (NAALADL-1), and transferrin receptor 1 (TfR1) as extracellular targets with the highest similarity to PSMA. The affinity of compound 1 for PSMA, GCPIII, NAALADL-1, and TfR1 was measured by fluorescence polarization. The expression of the putative anti-target GCPIII was assessed by immunofluorescence on human salivary glands and kidney, using commercially available antibodies. RESULTS: A fluorescent derivative of Pluvicto™ (compound 1) bound tightly to PSMA and to GCPIII in fluorescence polarization experiments, while no interaction was observed with NAALADL-1 and TfR1. Immunofluorescence analysis revealed abundant expression of GCPIII both in healthy human kidney and salivary glands. CONCLUSION: We conclude that the membranous expression of GCPIII in kidney and salivary gland may be the underlying cause for unwanted accumulation of Pluvicto™ and other Glu-ureido PSMA radio pharmaceuticals in patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lucaroni L, Georgiev T, Prodi E, et al. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics. Eur J Nucl Med Mol Imaging. 2022. PMID: 36184692. doi:10.1007/s00259-022-05982-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。